Urticaria and angiedema-like skin reactions in a patient treated with adalimumab

Loading...
Thumbnail Image

Date

Authors

Nikas, S. N.
Voulgari, P. V.
Drosos, A. A.

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Type of the conference item

Journal type

peer-reviewed

Educational material type

Conference Name

Journal name

Clin Rheumatol

Book name

Book series

Book edition

Alternative title / Subtitle

Description

Specific inhibition of the cytokine tumor necrosis factor alpha has resulted in significant clinical and laboratory improvement of patients with chronic inflammatory diseases of Th1 phenotype. Etanercept is a recombinant fusion protein of two p75 soluble receptors, while infliximab is a chimeric monoclonal antibody. Both have been considered to be immunogenic and cause various immune-mediated skin reactions. On the other hand, adalimumab, a human monoclonal antibody, was expected to cause little or no immune-mediated skin reactions. Herein, we report a patient with rheumatoid arthritis treated with adalimumab, who after the seventh injection, developed angiedema affecting the lips and face, as well as an urticaria-like skin reaction affecting the trunk. These reactions were followed by hypotension. The patient was treated appropriately and after 2 h, the rashes and the edema disappeared and the patient gradually recovered completely. Adalimumab was discontinued.

Description

Keywords

Antibodies, Monoclonal/*adverse effects, Antibodies, Monoclonal, Humanized, Antirheumatic Agents/*adverse effects, Arthritis, Rheumatoid/*drug therapy, Female, Humans, Middle Aged, Urticaria/*chemically induced

Subject classification

Citation

Link

http://www.ncbi.nlm.nih.gov/pubmed/16421645
http://www.springerlink.com/content/p4kx2254886309xv/fulltext.pdf

Language

en

Publishing department/division

Advisor name

Examining committee

General Description / Additional Comments

Institution and School/Department of submitter

Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής

Table of contents

Sponsor

Bibliographic citation

Name(s) of contributor(s)

Number of Pages

Course details

Endorsement

Review

Supplemented By

Referenced By